The Gastrointestinal Radiation Toxicity drugs in development market research report provides comprehensive information on the therapeutics under development for Gastrointestinal Radiation Toxicity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gastrointestinal Radiation Toxicity. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gastrointestinal Radiation Toxicity and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Gastrointestinal Radiation Toxicity by six companies/universities/institutes. The top development phase for Gastrointestinal Radiation Toxicity is preclinical with six drugs in that stage. The Gastrointestinal Radiation Toxicity pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Gastrointestinal Radiation Toxicity pipeline products market are: New Amsterdam Sciences, RepoCeuticals and Ceramedix Holding.
The key targets in the Gastrointestinal Radiation Toxicity pipeline products market include Ceramide Glucosyltransferase (Glucosylceramide Synthase or GLCT 1 or UDP Glucose:N Acylsphingosine D Glucosyltransferase or UDP Glucose Ceramide Glucosyltransferase or UGCG or EC 2.4.1.80), Sphingosine Kinase 2 (SK2 or SPK 2 or SPHK2 or EC 2.7.1.91), and Substance P Receptor (Tachykinin Receptor 1 or NK 1 Receptor or NK1R or TACR1).
The key mechanisms of action in the Gastrointestinal Radiation Toxicity pipeline product include Ceramide Glucosyltransferase (Glucosylceramide Synthase or GLCT 1 or UDP Glucose:N Acylsphingosine D Glucosyltransferase or UDP Glucose Ceramide Glucosyltransferase or UGCG or EC 2.4.1.80) Inhibitor with two drugs in Preclinical. The Gastrointestinal Radiation Toxicity pipeline products include ten routes of administration with the top ROA being Oral and three key molecule types in the Gastrointestinal Radiation Toxicity pipeline products market including Small Molecule, and Antibody.
Gastrointestinal Radiation Toxicity overview
Gastrointestinal radiation toxicity occurs following external beam therapy with respect to the gastrointestinal tract, the severity of toxicity is reported as grades to different symptoms or clinical manifestations ranging from minor symptomatic changes to severe life threatening complications.
For a complete picture of Gastrointestinal Radiation Toxicity’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
